Epigenetic regulation of Dapper family proteins in cancer

doi:10.12092/j.issn.1009-2501.2019.12.017

Abstract

Abstract:

Dapper family proteins regulate the Wnt signaling pathway and are closely related to cancer initiation and progression. Dapper proteins usually are highly expressed in the normal tissues but often reduced or completely lost in tumors.S uch reduction in expression is mediated by the epigenetic regulation and associated with pathological characteristics, cancer progression and prognosis. Here we review the most recent discoveries in biological functions of Dapper family proteins in cancer initiation and progression as well as the mechanism underlying the epigenetic regulation of the expression of Dapper family proteins.

Key words: Dapper, epigenetics, tumor suppressor gene, Wnt signaling pathway

CLC Number:

R968
R73

WU Juan, WU Yongjun, LI Zhi, ZENG Chang, LI Zhenfeng, TANG Yi, LU Miao, ZHANG Xuechun, ZHANG Wanyong, WANG Danhui, LIU Chenrui. Epigenetic regulation of Dapper family proteins in cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1434-1440.

References

［1］Suriben R,Fisher DA,Cheyette BN.Dact1 presomitic mesoderm expression oscillates in phase with Axin2 in the somitogenesis clock of mice［J］.Dev Dyn，2006，235(11):3177-3183.
［2］Xu H, Xiao Z,Zhang J,et al.Disruption of the Dapper3 gene aggravates ureteral obstruction-mediated renal fibrosis by amplifying Wnt/beta-catenin signaling［J］.J Biol Chem,2013，288(21):15006-15014.
［3］Ma B,Liu B,Cao W,et al.The Wnt signaling antagonist Dapper1 Accelerates dishevelled2 degradation via promoting its ubiquitination and aggregate-induced autophagy［J］.J Biol Chem,2015，290(19):12346-12354.
［4］Schussel JL,Kalinke LP,Sassi LM,et al.Expression and epigenetic regulation of DACT1 and DACT2 in oral squamous cell carcinoma［J］.Cancer Biomark,2015，15(1):11-17.
［5］Yin X,Xiang T,Li L,et al.DACT1,an antagonist to Wnt/beta-catenin signaling,suppresses tumor cell growth and is frequently silenced in breast cancer［J］.Breast Cancer Res,2013，15(2):R23.
［6］Gao J,Zhao C,Liu Q,et al.Cyclin G2 suppresses Wnt/beta-catenin signaling and inhibits gastric cancer cell growth and migration through Dapper1［J］.J Exp Clin Cancer Res,2018，37(1):317.
［7］Tan Y, Li QM,Huang N,et al.Upregulation of DACT2 suppresses proliferation and enhances apoptosis of glioma cell via inactivation of YAP signaling pathway［J］.Cell Death Dis,2017，8(8): e2981.
［8］Xiang T,Fan Y,Li C,et al.DACT2 silencing by promoter CpG methylation disrupts its regulation of epithelial-to-mesenchymal transition and cytoskeleton reorganization in breast cancer cells［J］.Oncotarget,2016，7(43):70924-70935.
［9］Hou J,Liao LD,Xie YM,et al.DACT2 is a candidate tumor suppressor and prognostic marker in esophageal squamous cell carcinoma［J］.Cancer Prev Res (Phila),2013，6(8): 791-800.
［10］Wang S,Dong Y,Zhang Y,et al.DACT2 is a functional tumor suppressor through inhibiting Wnt/beta-catenin pathway and associated with poor survival in colon cancer［J］.Oncogene,2015，34(20): 2575-2585.
［11］Zhao Z,Herman JG,Brock MV, et al.Methylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signaling［J］.PLoS One,2014，9(11): e112336.
［12］Fan J,Zhang Y,Mu J,et al.TET1 exerts its anti-tumor functions via demethylating DACT2 and SFRP2 to antagonize Wnt/beta-catenin signaling pathway in nasopharyngeal carcinoma cells［J］.Clin Epigenetics, 2018，10(1):103.
［13］Liu Y, Zhang J,Yu W,et al.Dapper homolog 1 alpha suppresses metastasis ability of gastric cancer through inhibiting planar cell polarity pathway［J］.Oncotarget,2016，7(49):81423-81434.
［14］Katoh M,M Katoh.Identification and characterization of human DAPPER1 and DAPPER2 genes in silico［J］.Int J Oncol,2003，22(4):907-913.
［15］Danieau G,Morice S,Redini F, et al.New insights about the Wnt/beta-catenin signaling pathway in primary bone tumors and their microenvironment:a promising target to develop therapeutic strategies［J］.Int J Mol Sci,2019，20(15):103-110.
［16］Boutros M,Paricio N,Strutt DI,et al.Dishevelled activates JNK and discriminates between JNK pathways in planar polarity and wingless signaling［J］.Cell,1998，94(1):109-118.
［17］Wu HC,Southey MC,Hibshoosh H,et al.DNA methylation in breast tumor from high-risk women in the Breast Cancer Family Registry［J］.Anticancer Res,2017，37(2):659-664.
［18］Li L,Li C,Mao H,et al.Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers［J］.Sci Rep,2016，6（6）:26591.
［19］V Subramaniam A,Yehya AHS,Cheng WK,et al.Epigenetics:The master control of endothelial cell fate in cancer［J］.Life Sci,2019,232(232)：116652.
［20］Klutstein M,Nejman D, Greenfield R,et al.DNA Methylation in Cancer and Aging［J］.Cancer Res,2016,76(12):3446-3450.
［21］Yu Y,Yan W,Liu X,et al.DACT2 is frequently methylated in human gastric cancer and methylation of DACT2 activated Wnt signaling［J］.Am J Cancer Res,2014,4(6):710-724.
［22］Zhang Y,Fan J,Fan Y,et al.The new 6q27 tumor suppressor DACT2,frequently silenced by CpG methylation,sensitizes nasopharyngeal cancer cells to paclitaxel and 5-FU toxicity via beta-catenin/Cdc25c signaling and G2/M arrest［J］.Clin Epigenetics,2018,10(1):26.
［23］Jia Y,Yang Y,Brock MV,et al.Epigenetic regulation of DACT2,a key component of the Wnt signalling pathway in human lung cancer［J］.J Pathol,2013,230(2):194-204.
［24］Zhang X,Yang Y,Liu X,et al.Epigenetic regulation of the Wnt signaling inhibitor DACT2 in human hepatocellular carcinoma［J］.Epigenetics,2013,8(4):373-382.
［25］Li J,Zhang M,He T, et al.Methylation of DACT2 promotes breast cancer development by activating Wnt signaling［J］.Sci Rep,2017,7(1):3325.
［26］Guo YL,Shan BE,Guo W,et al.Aberrant methylation of DACT1 and DACT2 are associated with tumor progression and poor prognosis in esophageal squamous cell carcinoma［J］.J Biomed Sci,2017,24(1):6.
［27］Yau TO,Chan CY,Chan KL,et al.HDPR1,a novel inhibitor of the WNT/beta-catenin signaling,is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing［J］.Oncogene,2005,24(9):1607-1614.
［28］Cheng H,Deng Z,Wang Z,et al.The role of aberrant promoter hypermethylation of DACT1 in bladder urothelial carcinoma［J］.J Biomed Res,2012,26(5):319-324.
［29］Wang S, Kang W,Go MY,et al.Dapper homolog 1 is a novel tumor suppressor in gastric cancer through inhibiting the nuclear factor-kappaB signaling pathway［J］.Mol Med,2012,18（18）:1402-1411.
［30］Li RN,Liu B,Li XM,et al.DACT1 Overexpression in type I ovarian cancer inhibits malignant expansion and cis-platinum resistance by modulating canonical Wnt signalling and autophagy［J］.Sci Rep,2017,7(1):9285.
［31］Fu LN,Tan J, Chen YX,et al.Genetic variants in the histone methylation and acetylation pathway and their risks in eight types of cancers［J］.J Dig Dis,2018,19(2):102-111.
［32］Bartke T,Vermeulen M,Xhemalce B,et al.Nucleosome-interacting proteins regulated by DNA and histone methylation［J］.Cell,2010,143(3):470-484.
［33］Jiang X,Tan J,Li J,et al.DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications［J］.Cancer Cell,2008,13(6):529-241.
［34］Richmond TJ,CA Davey.The structure of DNA in the nucleosome core［J］.Nature,2003,423(6936):145-150.
［35］Requena F,Asenjo HG,Barturen G,et al.NOMePlot: analysis of DNA methylation and nucleosome occupancy at the single molecule［J］.Sci Rep,2019,9(1):8140.
［36］Lorch Y,RD Kornberg.Chromatin-remodeling and the initiation of transcription［J］.Q Rev Biophys,2015,48(4):465-470.
［37］Chodavarapu RK,Feng S,Bernatavichute YV,et al.Relationship between nucleosome positioning and DNA methylation［J］.Nature,2010,466(7304):388-392.
［38］Lu L,Wang Y,Ou R,et al.DACT2 epigenetic stimulator exerts dual efficacy for colorectal cancer prevention and treatment［J］.Pharmacol Res,2018,129（129）:318-328.
［39］Roy A,Palli SR.Epigenetic modifications acetylation and deacetylation play important roles in juvenile hormone action［J］.BMC genomics,2018,19(1):934.

[1]	SHEN Lei, WANG Keke, YANG Jingke, ZHAO Juntao, MENG Xiangguang, YUAN Yiqiang. Advances in drugs and genetic pharmacology for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 343-349.
[2]	KUANG Ze-min, HUANG Zhi-jun, YANG Guo-ping, YUAN Hong. Apparent pharmacogenetics in antihypertensive therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 351-355.